Abstract
Administration of adefovir dipivoxil (ADV) has been shown to provide an increased rate of hepatitis Be (HBe) seroconversion. It is also effective in the treatment of HIV. Because of its significant nephrotoxicity after 24 weeks of the treatment, this drug is no longer used for management of HIV. However, hepatitis B virus is inhibited with lower doses of ADV. The drug can even be used safely in those with renal impairment. This review provides new aspects of treatment of hepatitis B using ADV, especially in patients with renal dysfunction as well as renal transplant recipients. We showed that ADV can be used as a safe drug in renal transplant recipients.
Keywords
Full Text
Full text is available in PDF
Copyright
© 0, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.